Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
68% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AKBA' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: 12424.6
Current: No Debt
N/A
12424.6
Interest Coverage No Debt
AKBA's Interest Coverage is ranked lower than
69% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
Z-Score: 18.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -33.85
AKBA's ROE (%) is ranked lower than
52% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. AKBA: -33.85 )
Ranked among companies with meaningful ROE (%) only.
AKBA' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -33.85
ROA (%) -31.96
AKBA's ROA (%) is ranked lower than
54% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. AKBA: -31.96 )
Ranked among companies with meaningful ROA (%) only.
AKBA' s 10-Year ROA (%) Range
Min: -71.35  Med: -61.10 Max: -50.85
Current: -31.96
-71.35
-50.85
ROC (Joel Greenblatt) (%) -16721.22
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. AKBA: -16721.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AKBA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106220  Med: -68918.34 Max: -31616.67
Current: -16721.22
-106220
-31616.67
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 36.50
AKBA's Forward P/E is ranked lower than
72% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. AKBA: 36.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.08
AKBA's P/B is ranked higher than
79% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. AKBA: 2.08 )
Ranked among companies with meaningful P/B only.
AKBA' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 9.5
Current: 2.08
0
9.5
Current Ratio 11.62
AKBA's Current Ratio is ranked higher than
79% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. AKBA: 11.62 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s 10-Year Current Ratio Range
Min: 8.57  Med: 17.21 Max: 26.43
Current: 11.62
8.57
26.43
Quick Ratio 11.62
AKBA's Quick Ratio is ranked higher than
80% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AKBA: 11.62 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s 10-Year Quick Ratio Range
Min: 8.57  Med: 17.21 Max: 26.43
Current: 11.62
8.57
26.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.19
AKBA's Price/Net Cash is ranked higher than
90% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. AKBA: 2.19 )
Ranked among companies with meaningful Price/Net Cash only.
AKBA' s 10-Year Price/Net Cash Range
Min: 2.32  Med: 3.14 Max: 4.71
Current: 2.19
2.32
4.71
Price/Net Current Asset Value 2.14
AKBA's Price/Net Current Asset Value is ranked higher than
89% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. AKBA: 2.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AKBA' s 10-Year Price/Net Current Asset Value Range
Min: 2.29  Med: 3.10 Max: 4.65
Current: 2.14
2.29
4.65
Price/Tangible Book 2.12
AKBA's Price/Tangible Book is ranked higher than
83% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. AKBA: 2.12 )
Ranked among companies with meaningful Price/Tangible Book only.
AKBA' s 10-Year Price/Tangible Book Range
Min: 2.28  Med: 3.10 Max: 4.63
Current: 2.12
2.28
4.63
Earnings Yield (Greenblatt) (%) -22.01
AKBA's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. AKBA: -22.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AKBA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -94.7  Med: 0.00 Max: 0
Current: -22.01
-94.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Edited Transcript of AKBA presentation 1-Jun-15 6:00pm GMT Jun 26 2015
Coverage initiated on Akebia Therapeutics by JMP Securities Jun 22 2015
Akebia to Present at the 2015 JMP Securities Life Sciences Conference Jun 16 2015
Akebia to Present at the 2015 JMP Securities Life Sciences Conference Jun 16 2015
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 15 2015
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 11 2015
Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia... May 29 2015
Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia... May 29 2015
Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia... May 29 2015
Akebia to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
Akebia to Present at the Jefferies 2015 Global Healthcare Conference May 26 2015
Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual... May 26 2015
Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual... May 26 2015
AKEBIA THERAPEUTICS, INC. Financials May 20 2015
Akebia Shares Could More Than Double in a Year May 14 2015
Akebia to Present at the 2015 UBS Global Healthcare Conference May 12 2015
Akebia to Present at the 2015 UBS Global Healthcare Conference May 12 2015
Akebia Announces First Quarter 2015 Financial Results May 11 2015
Akebia Therapeutics reports 1Q loss May 11 2015
AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK